Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3

There’s a pivotal trial in the offing for Pfizer and Sangamo’s hemophilia A gene therapy, but, in the meantime, the duo is unveiling updated phase 1/2 data. The highest dose of the treatment helped patients make functioning blood-clotting factors for a sustained period, underlining its potential to free hemophilia A patients from lifelong treatment.